Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in